A citation-based method for searching scientific literature

R M Hofstra, R M Landsvater, I Ceccherini, R P Stulp, T Stelwagen, Y Luo, B Pasini, J W Höppener, H K van Amstel, G Romeo. Nature 1994
Times Cited: 942







List of co-cited articles
953 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
929
53

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
53

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
H Donis-Keller, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells. Hum Mol Genet 1993
41

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
28

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
K M Carlson, S Dou, D Chi, N Scavarda, K Toshima, C E Jackson, S A Wells, P J Goodfellow, H Donis-Keller. Proc Natl Acad Sci U S A 1994
518
27

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
C Eng, D P Smith, L M Mulligan, M A Nagai, C S Healey, M A Ponder, E Gardner, G F Scheumann, C E Jackson, A Tunnacliffe. Hum Mol Genet 1994
439
24


RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
293
22

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
20

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
570
17

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
M Santoro, F Carlomagno, A Romano, D P Bottaro, N A Dathan, M Grieco, A Fusco, G Vecchio, B Matoskova, M H Kraus. Science 1995
703
16

RET tyrosine kinase signaling in development and cancer.
Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
306
16

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
162
16

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
195
16

Guidelines for diagnosis and therapy of MEN type 1 and type 2.
M L Brandi, R F Gagel, A Angeli, J P Bilezikian, P Beck-Peccoz, C Bordi, B Conte-Devolx, A Falchetti, R G Gheri, A Libroia,[...]. J Clin Endocrinol Metab 2001
15

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
D J Marsh, D L Learoyd, S D Andrew, L Krishnan, R Pojer, A L Richardson, L Delbridge, C Eng, B G Robinson. Clin Endocrinol (Oxf) 1996
156
15

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
113
15

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
615
14

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
773
13

Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective.
Michael Brauckhoff, Andreas Machens, Kerstin Lorenz, Trine Bjøro, Jan Erik Varhaug, Henning Dralle. Ann Surg 2014
47
27

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
896
13

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
M Grieco, M Santoro, M T Berlingieri, R M Melillo, R Donghi, I Bongarzone, M A Pierotti, G Della Porta, A Fusco, G Vecchio. Cell 1990
817
12

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
272
12

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
186
12

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
811
11

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
E Modigliani, R Cohen, J M Campos, B Conte-Devolx, B Maes, A Boneu, M Schlumberger, J C Bigorgne, P Dumontier, L Leclerc,[...]. Clin Endocrinol (Oxf) 1998
351
11

Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
Rebecca L Margraf, David K Crockett, Patti M F Krautscheid, Ryan Seamons, Fernanda R O Calderon, Carl T Wittwer, Rong Mao. Hum Mutat 2009
98
11

Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis.
Michael Brauckhoff, Andreas Machens, Sören Hess, Kerstin Lorenz, Oliver Gimm, Katrin Brauckhoff, Carsten Sekulla, Henning Dralle. Surgery 2008
57
19


Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
L M Mulligan, C Eng, C S Healey, D Clayton, J B Kwok, E Gardner, M A Ponder, A Frilling, C E Jackson, H Lehnert. Nat Genet 1994
545
11

Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study.
Jes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, Mette Madsen, Kirstine Stochholm, Per Løgstrup Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Sten Schytte, Henrik Baymler Pedersen,[...]. Endocr Relat Cancer 2017
24
45

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
319
11

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
12

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
11

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Taranjit S Gujral, Vinay K Singh, Zongchao Jia, Lois M Mulligan. Cancer Res 2006
55
18

Structure and chemical inhibition of the RET tyrosine kinase domain.
Phillip P Knowles, Judith Murray-Rust, Svend Kjaer, Rizaldy P Scott, Sarah Hanrahan, Massimo Santoro, Carlos F Ibáñez, Neil Q McDonald. J Biol Chem 2006
174
10

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
134
10

The GDNF family: signalling, biological functions and therapeutic value.
Matti S Airaksinen, Mart Saarma. Nat Rev Neurosci 2002
9

Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
Iván Plaza-Menacho, Karin Barnouin, Kerry Goodman, Rubén J Martínez-Torres, Annabel Borg, Judith Murray-Rust, Stephane Mouilleron, Phillip Knowles, Neil Q McDonald. Mol Cell 2014
45
20

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
52
17

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Margarida M Moura, Branca M Cavaco, António E Pinto, Valeriano Leite. J Clin Endocrinol Metab 2011
148
9

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
407
9


Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
200
9

Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.
Frederic Castinetti, Steven G Waguespack, Andreas Machens, Shinya Uchino, Kornelia Hasse-Lazar, Gabriella Sanso, Tobias Else, Sarka Dvorakova, Xiao Ping Qi, Rossella Elisei,[...]. Lancet Diabetes Endocrinol 2019
40
22

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).
Rajesh V Thakker, Paul J Newey, Gerard V Walls, John Bilezikian, Henning Dralle, Peter R Ebeling, Shlomo Melmed, Akihiro Sakurai, Francesco Tonelli, Maria Luisa Brandi. J Clin Endocrinol Metab 2012
647
8

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Samuel A Wells, Furio Pacini, Bruce G Robinson, Massimo Santoro. J Clin Endocrinol Metab 2013
180
8

Early malignant progression of hereditary medullary thyroid cancer.
Andreas Machens, Patricia Niccoli-Sire, Josef Hoegel, Karin Frank-Raue, Theo J van Vroonhoven, Hans-Dietrich Roeher, Robert A Wahl, Peter Lamesch, Friedhelm Raue, Bernard Conte-Devolx,[...]. N Engl J Med 2003
332
8


Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
A Boichard, L Croux, A Al Ghuzlan, S Broutin, C Dupuy, S Leboulleux, M Schlumberger, J M Bidart, L Lacroix. J Clin Endocrinol Metab 2012
90
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.